Letibotulinumtoxina

CHEMBL3707322 Phase 4 Approuvé Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A botulinum toxin type A preparation used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows in adults. It works by relaxing the underlying facial muscles through nerve signal blockade.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A botulinum toxin type A preparation used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows in adults. It works by relaxing the underlying facial muscles through nerve signal blockade.

Yes, Letibotulinumtoxina is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707322. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Letibotulinumtoxina sur PillFYI

Données Clés

Synonymes: 1

Liens externes

ChEMBL CHEMBL3707322

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.